Clinical Trial Update: Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating tislelizumab plus lenalidomide in refractory/relapsed elderly patients with various aggressive B-cell lymphomas, including non-GCB/AB…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alk-positive Anaplastic Large Cell Lymphoma
• Ebv-positive Dlbcl Nos
• Follicular Lymphoma Grade Iiib
• High-grade B-cell Lymphoma
• Non-gcb Abc Diffuse Large B-cell Lymphoma
• Transformed Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Huiqiang Huang | Conditions: Non-GCB/ABC Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1, Phase 2 | Status: UNKNOWN